Efficacy and Safety of Targeted Complement Inhibitors in Patients with C3 Glomerulopathy: A Systematic Review and Quantitative Synthesis of Randomized Controlled Trials (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0675; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Phase 2-3 randomized controlled trials (RCTs) investigating iptacopan, pegcetacoplan, or avacopan in adolescent and adults suffering from C3G diagnosed by biopsy were selected. Conclusion From the recent research conducted in our study, it is evident that complement inhibitors are an effective method that can be employed in managing C3 glomerulopathy (C3G), particularly proteinuria reduction. However, additional research is still required to validate this Results"
Clinical • Review • Complement-mediated Rare Disorders • Glomerulonephritis • Nephrology • Renal Disease
|
|
Ahmad Bouhuwaish; Shahd Husayn Sakran; Sarah Elmabri Bouhuwaish; Muner Mohamed
|